ADHD Study

About The Study

The 812P401 Study is a clinical research study evaluating an investigational medication (SPN‑812) to see if it may help reduce ADHD symptoms in preschool-age children. SPN-812 is approved by the U.S. Food and Drug Administration (FDA) as Qelbree and is used for the treatment of ADHD in pediatric patients ages 6 to 17.

The study lasts about 10 weeks and includes clinic visits, ADHD evaluations, and study-related care at no cost. Families who qualify may also be eligible to join an optional extension study where all children receive the active medication.

Quick Facts

Study Visits

Conducted in Atlanta, GA 30318, United States

For Preschoolers

Children between 4 years 0 months and 5 years 9 months may qualify.

Commitment

Study lasts about 10 weeks with ~8 clinic visits

Compensation

Families may receive up to $825 for participation

Your child may qualify if:

He or she is between 4 years and 5 years 9 months of age
Has confirmed ADHD diagnosis (or symptoms severe enough to require treatment)
Has tried a course of non-medication treatment OR has symptoms severe enough to warrant treatment with medication
Is attending a structured group activity (such as preschool, kindergarten, sports, Sunday school, or childcare)

What to Expect:

Screening & Evaluation: Your child will complete ADHD assessments and a physical exam to confirm eligibility.

Study Medication: Daily oral dose of SPN‑812 or placebo for 6 weeks.

Clinic Visits: About 8 visits over the 10-week study, plus a follow-up phone call.

Extension Opportunity: After completing the study, your child may join an extension where all children receive the active medication.

Compensation &
Benefits

Families may receive up to $825 for completing all study visits.

All ADHD evaluations, physical exams, study medication, and study-related care are provided at no cost.
Travel reimbursement may also be available.

This is an opportunity to contribute to research on ADHD in preschoolers while receiving close medical oversight and support from experienced professionals.

sign-up

FAQ

We’ve pulled together some basics to help you get started

How long does the study last?

About 10 weeks, including screening, 6 weeks of treatment, and a follow-up call.

What does it cost to participate?

There is no cost. All study-related evaluations, care, and medication are provided free of charge.

Will my child get the active medication?

During the main study, children are randomly assigned to SPN‑812 or placebo. After completing the study, you may enroll your child in an extension study with active medication only.

How much compensation will we receive?

Families may receive up to $825 for participation and may be reimbursed for certain study-related expenses.

Join a study on Attention Deficit/Hyperactivity Disorder in 4 and 5 year olds